| Sector |
Healthcare
|
Compare with Sector peers |
| Industry |
Pharmaceuticals & Drugs
|
Compare with Industry peers |
| Website | http://www.tridentlifeline.com | |
| Market Cap | 164.44 Cr. | |
| Enterprise Value(EV) | 166.76 Cr. | 2022-03 |
| Financial Indicators | ||
|---|---|---|
| Earnings per share (EPS) | 1.96 | Trailing Twelve Months Ending 2022-03 |
| Price-Earning Ratio (PE) | 73.12 | Trailing Twelve Months Ending 2022-03 |
| Industry PE | 32.17 | Trailing Twelve Months Ending 2022-03 |
| Book Value / Share | 36.64 | Trailing Twelve Months Ending 2022-03 |
| Price to Book Value | 3.90 | Calculated using Price: 143.00 |
| Dividend Yield | 0.00 | Period Ending 2022-03 |
| No. of Shares Subscribed | 1.15 Cr. | 11,499,200 Shares |
| FaceValue | 10 | |
| Company Profile | ||
| No Company Profile found. | ||
| 1 Day |
|
-3.87% |
| 1 Week |
|
-4.03% |
| 1 Month |
|
-6.96% |
| 3 Month |
|
+15.32% |
| 6 Month |
|
|
| 1 Year |
|
|
| 2 Year |
|
|
| 5 Year |
|
|
| 10 Year |
|
| 1 years | 2022-03 | |
| Return on Equity (%) | 47.75 | |
| Return on Capital Employed (%) | 44.06 | |
| Return on Assets (%) | 17.88 |
| Particulars | 1 years | 2022-03 Rs. Cr. |
| Shh. Funds | 5 | |
| Non Curr. Liab. | 0 | |
| Curr. Liab. | 8 | |
| Minority Int. | ||
| Equity & Liab. | 13 | |
| Non Curr. Assets | 2 | |
| Curr. Assets | 11 | |
| Misc. Exp. not W/O | ||
| Total Assets | 13 |
| Particulars | 1 years | 2022-03 Rs. Cr. |
| Net Sales | 22 | |
| Other Income | 1 | |
| Total Income | 22 | |
| Total Expenditure | -19 | |
| PBIDT | 3 | |
| Interest | 0 | |
| Depreciation | 0 | |
| Taxation | -1 | |
| Exceptional Items | ||
| PAT | 2 | |
| Minority Interest | ||
| Share Associate | 0 | |
| Other Related Items | ||
| Consolidated Net Profit | 2 | |
| Adjusted EPS | 3 |
| Particulars | 1 years | 2022-03 Rs. Cr. |
| Cash Fr. Operatn. | 0 | |
| Cash Fr. Inv. | 0 | |
| Cash Fr. Finan. | 1 | |
| Net Change | 0 | |
| Cash & Cash Eqvt | 0 |
|
Thu, 30 Mar 2023
Closure of Trading Window Pursuant to SEBI (Prohibition of Insider Trading) Regulations 2015 we wish to inform you that the Trading Window for dealing in securities of the Company shall remain closed with effect from 1st April 2023 and shall be opened 48 (Forty-Eight) hours after the conclusion of the Meeting of the Board of Directors to be held for the purpose of considering the Audited Financial Results for the year ending 31st March 2023.The date of the Board Meeting for the aforesaid purpose shall be intimated to you separately. |
|
Sat, 04 Feb 2023
Submission Of Consolidated Limited Review Report For The Quarter And Nine Months Ended 31St December 2022. With reference to your email dated 03rd February 2022 regarding the discrepancies in Consolidated Results for the quarter and nine months ended 31st December 2022 -Limited Review Report not submitted for Consolidated Financial Result for Quarter Ended - December 2022 we hereby furnish the Limited Review Report for ConsolidatedFinancial Results for the quarter and nine months ended 31st December 2022 as we erroneously failed to furnish the same.Also there is no change in any of the figures and details submitted earlier. |
|
Sat, 04 Feb 2023
Submission Of Consolidated Limited Review Report For The Quarter And Nine Months Ended December 31 2022. With reference to your email dated 03rd February 2022 regarding the discrepancies in Consolidated Results for the quarter and nine months ended December 31 2022 - Limited Review Report not submitted for Consolidated Financial Result for Quarter Ended - December 2022 we hereby furnish the Limited Review Report for Consolidated Financial Results for the quarter and nine months ended 31st December 2022 as we erroneously failed to furnish the same.Also there is no change in any of the figures and details submitted earlier. |
| Wed, 29 Mar 2023 |
High Delivery Percentage
|
Higher Delivery Quantity
|
Higher Delivery Quantity and Percentage
|
Higher Trade Quantity
|
Higher Trade and Delivery Quantity
|
Equities
M.F.
Sectors